EDAP TMS S.A. (FOCL)
Nasdaq · Healthcare · Medical Distribution
$4.23+0.71%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $200M
- 52-week range
- $1.75 – $6.40
- 52-week change
- +90.91%
- EPS (trailing)
- −$1.39
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $70.5M (+1.63%)
- Net income
- −$29.2M
- Operating margin
- −35.0%
- Diluted EPS
- −$0.78
From the company’s annual report on SEC EDGAR.
About EDAP TMS S.A.
EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents.
Headquarters: Vaulx-En-Velin, France · 289 employees · investor.focalone.com